Cargando…
Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition in patients who have received chemotherapy. The role of neuromodulation therapy in treating pain and improving neurological function in CIPN remains unclear and warrants evidence appraisal. In compliance with t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405804/ https://www.ncbi.nlm.nih.gov/pubmed/36009456 http://dx.doi.org/10.3390/biomedicines10081909 |
_version_ | 1784773967020556288 |
---|---|
author | D’Souza, Ryan S. Her, Yeng F. Jin, Max Y. Morsi, Mahmoud Abd-Elsayed, Alaa |
author_facet | D’Souza, Ryan S. Her, Yeng F. Jin, Max Y. Morsi, Mahmoud Abd-Elsayed, Alaa |
author_sort | D’Souza, Ryan S. |
collection | PubMed |
description | Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition in patients who have received chemotherapy. The role of neuromodulation therapy in treating pain and improving neurological function in CIPN remains unclear and warrants evidence appraisal. In compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review to assess change in pain intensity and neurological function after implementation of any neuromodulation intervention for CIPN. Neuromodulation interventions consisted of dorsal column spinal cord stimulation (SCS), dorsal root ganglion stimulation (DRG-S), or peripheral nerve stimulation (PNS). In total, 15 studies utilized SCS (16 participants), 7 studies utilized DRG-S (7 participants), and 1 study utilized PNS (50 participants). Per the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria, there was very low-quality GRADE evidence supporting that dorsal column SCS, DRG-S, and PNS are associated with a reduction in pain severity from CIPN. Results on changes in neurological function remained equivocal due to mixed study findings on thermal sensory thresholds and touch sensation or discrimination. Future prospective, well-powered, and comparative studies assessing neuromodulation for CIPN are warranted. |
format | Online Article Text |
id | pubmed-9405804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94058042022-08-26 Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review D’Souza, Ryan S. Her, Yeng F. Jin, Max Y. Morsi, Mahmoud Abd-Elsayed, Alaa Biomedicines Systematic Review Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition in patients who have received chemotherapy. The role of neuromodulation therapy in treating pain and improving neurological function in CIPN remains unclear and warrants evidence appraisal. In compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review to assess change in pain intensity and neurological function after implementation of any neuromodulation intervention for CIPN. Neuromodulation interventions consisted of dorsal column spinal cord stimulation (SCS), dorsal root ganglion stimulation (DRG-S), or peripheral nerve stimulation (PNS). In total, 15 studies utilized SCS (16 participants), 7 studies utilized DRG-S (7 participants), and 1 study utilized PNS (50 participants). Per the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria, there was very low-quality GRADE evidence supporting that dorsal column SCS, DRG-S, and PNS are associated with a reduction in pain severity from CIPN. Results on changes in neurological function remained equivocal due to mixed study findings on thermal sensory thresholds and touch sensation or discrimination. Future prospective, well-powered, and comparative studies assessing neuromodulation for CIPN are warranted. MDPI 2022-08-07 /pmc/articles/PMC9405804/ /pubmed/36009456 http://dx.doi.org/10.3390/biomedicines10081909 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review D’Souza, Ryan S. Her, Yeng F. Jin, Max Y. Morsi, Mahmoud Abd-Elsayed, Alaa Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review |
title | Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review |
title_full | Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review |
title_fullStr | Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review |
title_full_unstemmed | Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review |
title_short | Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review |
title_sort | neuromodulation therapy for chemotherapy-induced peripheral neuropathy: a systematic review |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405804/ https://www.ncbi.nlm.nih.gov/pubmed/36009456 http://dx.doi.org/10.3390/biomedicines10081909 |
work_keys_str_mv | AT dsouzaryans neuromodulationtherapyforchemotherapyinducedperipheralneuropathyasystematicreview AT heryengf neuromodulationtherapyforchemotherapyinducedperipheralneuropathyasystematicreview AT jinmaxy neuromodulationtherapyforchemotherapyinducedperipheralneuropathyasystematicreview AT morsimahmoud neuromodulationtherapyforchemotherapyinducedperipheralneuropathyasystematicreview AT abdelsayedalaa neuromodulationtherapyforchemotherapyinducedperipheralneuropathyasystematicreview |